Following a 4-week single-blind placebo run-in period, eligible subjects were randomized in a 1:1 ratio to receive 32 weeks of double-blind study medication: Rosiglitazone (starting dose 4mg od) or Glyburide (starting dose 5mg od), both in combination with open-label Metformin \> or = (1g/day). Subjects were stratified for use of ACEI, nondihydropyridine calcium channel blockers (NDP CCB), or angiotensin II receptor blockers (ARB) to provide equal representation of these subjects in each treatment group.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
336
The primary efficacy endpoint was percent change from baseline in ACR after 32 weeks of treatment.
Time frame: 32 Weeks
Secondary efficacy endpoints included change from baseline (visit 3) at week 32 (visit 7) in the following: serum TGF, creatinine clearance (calculated), PAI-1, CRP, IL-6, vWF, sVCAM, fibrinogen, TNF alpha, ET-1, heart rate and blood pressure
Time frame: 32 Weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Tempe, Arizona, United States
GSK Investigational Site
Fullerton, California, United States
GSK Investigational Site
Long Beach, California, United States
GSK Investigational Site
Mission Viejo, California, United States
GSK Investigational Site
Pasadena, California, United States
GSK Investigational Site
Redwood City, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
Santa Barbara, California, United States
...and 103 more locations